PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för venetoclax. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

25 hits

Bibliografisk träff 2017-03-01

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.

Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A, Russell N.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.8742

Bibliografisk träff 2016-08-01

Venetoclax (Venclexta) for chronic lymphocytic leukemia.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2016-08-01

Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.

Författaruppgift saknas

Clin Cancer Res · published erratum; journal article · DOI 10.1158/1078-0432.ccr-16-1315

Bibliografisk träff 2016-06-10

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.

Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP, Wood KC.

Sci Rep · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/srep27696

Bibliografisk träff 2016-06-01

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.9185

Bibliografisk träff 2016-05-01

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.

Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman ME.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.8547

Bibliografisk träff 2016-04-21

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Xiang S, Zhang X, Chu R, Wang ZJ, Lin H, Taub JW, Ge Y.

Clin Cancer Res · research-article; journal article · DOI 10.1158/1078-0432.ccr-15-3057

Bibliografisk träff 2016-04-19

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.

Bojarczuk K, Sasi BK, Gobessi S, Innocenti I, Pozzato G, Laurenti L, Efremov DG.

Blood · journal article · DOI 10.1182/blood-2015-10-675009

Bibliografisk träff 2016-03-31

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199.

García CP, Videla Richardson GA, Dimopoulos NA, Fernandez Espinosa DD, Miriuka SG, Sevlever GE, Romorini L, Scassa ME.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0152607

Bibliografisk träff 2016-03-11

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leverson JD.

Blood Cancer J · published erratum; correction · DOI 10.1038/bcj.2016.12

Bibliografisk träff 2016-02-24

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.

Weiss J, Gajek T, Köhler BC, Haefeli WE.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics8010005

Bibliografisk träff 2016-01-16

Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.

Song T, Chai G, Liu Y, Yu X, Wang Z, Zhang Z.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bph.13370

Bibliografisk träff 2015-12-17

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.celrep.2015.12.003

Bibliografisk träff 2015-11-20

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.

Cang S, Iragavarapu C, Savooji J, Song Y, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/s13045-015-0224-3

Bibliografisk träff 2015-11-13

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leverson JD.

Blood Cancer J · research-article; journal article · DOI 10.1038/bcj.2015.88

Bibliografisk träff 2015-10-14

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.

Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K, Vockova P, Lateckova L, Molinsky J, Maswabi BC, Alam M, Kodet R, Pytlik R, Trneny M, Klener P.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-15-1191

Bibliografisk träff 2015-09-01

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.

Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, McGonigal T, Mishra S, Schlessinger S, Smith ML, Tahir SK, Leverson JD, Souers AJ, Boghaert ER, Hickson J.

Pharmacol Res Perspect · research-article; journal article · DOI 10.1002/prp2.178

Bibliografisk träff 2015-08-01

Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.

Montraveta A, Xargay-Torrent S, Rosich L, López-Guerra M, Roldán J, Rodríguez V, Lee-Vergés E, de Frías M, Campàs C, Campo E, Roué G, Colomer D.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.4230

Bibliografisk träff 2015-05-08

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E.

Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2015.124560

Bibliografisk träff 2015-04-17

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.

Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH.

Leukemia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2015.99

Bibliografisk träff 2015-03-31

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-14-2809

Bibliografisk träff 2014-10-01

ABT-199 for chronic lymphocytic leukemia.

Seymour J.

Clin Adv Hematol Oncol · interview

Bibliografisk träff 2014-08-01

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

Författaruppgift saknas

Clin Adv Hematol Oncol · journal article

Bibliografisk träff 2014-07-15

ABT-199 partners with azacitidine to contest myeloid malignancies.

Wei A.

Leuk Lymphoma · comment; journal article · DOI 10.3109/10428194.2014.919638

Bibliografisk träff 2014-07-03

ABT-199 shows effectiveness in CLL.

Författaruppgift saknas

Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2014-102